Viridian Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Viridian Therapeutics de winst en omzet met respectievelijk 33.8% en 74% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 36.2% per jaar.

Belangrijke informatie

33.8%

Groei van de winst

36.2%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	74.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Recent updates

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Winst- en omzetgroeiprognoses

NasdaqCM:VRDN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	54	-305	-233	-237	9
12/31/2025	0	-298	-246	-287	13
12/31/2024	0	-251	-191	-197	13
6/30/2024	0	-228	-169	-168	N/A
3/31/2024	0	-218	-168	-167	N/A
12/31/2023	0	-238	-185	-184	N/A
9/30/2023	0	-217	-181	-180	N/A
6/30/2023	1	-198	-163	-162	N/A
3/31/2023	2	-172	-136	-135	N/A
12/31/2022	2	-130	-95	-94	N/A
9/30/2022	2	-113	-77	-76	N/A
6/30/2022	1	-98	-68	-68	N/A
3/31/2022	2	-87	-65	-64	N/A
12/31/2021	3	-79	-55	-55	N/A
9/30/2021	3	-141	-48	-47	N/A
6/30/2021	3	-133	-41	-41	N/A
3/31/2021	2	-121	-33	-33	N/A
12/31/2020	1	-111	-30	-30	N/A
9/30/2020	2	-30	-28	-28	N/A
6/30/2020	3	-36	-32	-32	N/A
3/31/2020	5	-38	-33	-33	N/A
12/31/2019	4	-42	-36	-36	N/A
9/30/2019	4	-42	-37	-36	N/A
6/30/2019	4	-40	-34	-34	N/A
3/31/2019	4	-40	-32	-31	N/A
12/31/2018	8	-33	-27	-27	N/A
9/30/2018	9	-29	-26	-26	N/A
6/30/2018	10	-26	-25	-25	N/A
3/31/2018	8	-24	N/A	-27	N/A
12/31/2017	4	-27	N/A	-28	N/A
9/30/2017	3	-26	N/A	-24	N/A
6/30/2017	3	-24	N/A	-21	N/A
3/31/2017	3	-21	N/A	-19	N/A
12/31/2016	3	-17	N/A	-15	N/A
9/30/2016	4	-17	N/A	-14	N/A
12/31/2015	5	-16	N/A	-13	N/A
12/31/2014	8	-6	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VRDN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VRDN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VRDN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van VRDN ( 74% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van VRDN ( 74% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VRDN naar verwachting over 3 jaar hoog zal zijn

Viridian Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.5% to US$37.81

Consensus revenue estimates fall by 19%

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Recent updates

CEO, President & Director recently bought US$499k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Price target increased by 7.5% to US$37.81

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

New minor risk - Share price stability

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

Consensus revenue estimates fall by 19%

First half 2024 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer